CDC Narrows Age Recommendation for RSV Shots in U.S.
The U.S. CDC has revised its recommendation for respiratory syncytial virus (RSV) vaccines, now prioritizing adults 75 and older and those aged 60 to 74 with heightened risk due to medical conditions. Previously, RSV vaccines were advised for all adults 60 and older after consulting a healthcare provider.
This change, reflecting the advice of CDC’s panel of experts, aims to better target those at highest risk for severe RSV. The updated recommendation may reduce the immediate U.S. market for RSV vaccines from 93 million to about 55 million adults, but could improve vaccine uptake in the long term through simpler guidelines and enhanced insurance coverage for high-risk groups. Read more in Reuters here.